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Abstract
: An important principle in the good conduct of clinical trials is thatBackground
a summary of the trial protocol, with a pre-defined primary outcome, should be
freely available before the study commences. The clinical trials registry
ClinicalTrials.gov provides one method of doing this, and once the trial is
registered, any changes made to the primary outcome are documented. The
objectives of this study were: to assess the proportion of registered trials on
ClinicalTrials.gov that had the primary outcome changed; to assess when the
primary outcome was changed in relation to the listed study start and end dates
and to assess whether the primary outcome change had any relation to the
study sponsor.
: A cross-sectional analysis of all interventional clinical trialsMethods
registered on ClinicalTrials.gov as of 25 October 2012 was performed. The
main outcome was any change made to the initially listed primary outcome and
the time of the change in relation to the trial start and end date.
: Our analysis showed that 28229 of 89204 (31.7%) registered studiesFindings
had their primary outcome changed.  Industry funding was associated with all
primary outcome changes, odds ratio (OR)= 1.36, 95% confidence interval
(CI)=1.31-1.41, p<0.001; with primary outcome changes after study start date
OR=1.37, 95% CI=1.32-1.42, p<0.001; with primary outcome changes after
primary completion date OR=1.84, 95% CI=1.75-1.94, p<0.001 and with
primary outcome changes after study completion date OR=1.82, 95%
CI=1.73-1.91, p<0.001. 
 A significant proportion of interventional trials registered onConclusions
ClinicalTrials.gov have their primary outcomes altered after the listed study start
and completion dates. These changes are associated with funding source.
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Introduction
Clinical trials provide the principal method with which to assess the 
effectiveness of therapeutic strategies1. An important principle in 
the good conduct of clinical trials is that a summary of the trial pro-
tocol, with a pre-defined primary outcome, should be freely avail-
able before the study commences1. In February 2000, the United 
States (US) Food and Drug Administration (FDA) created an online 
clinical trials registry named ClinicalTrials.gov2. From 2005, the 
International Committee of Medical Journal Editors (ICMJE) 
required that clinical trials should be listed in a clinical trial registry 
to qualify for publication3. The registration of a clinical trial usually 
involves reporting informationon 20 items proposed by the World 
Health Organization (WHO) registration advisory group, including 
the primary outcome of the study4. One reason for the creation of 
this registry was to help to reduce the risk of selective reporting of 
outcomes that had been previously identified. For example, a cohort 
study using protocols and published reports of randomized trials 
approved by the Scientific-Ethical Committees for Copenhagen and 
Frederiksberg in Denmark in 1994–1995 found that 62% of trials 
had at least one primary outcome that was changed, introduced, or 
omitted5. A more recent study looking at trials that were registered 
on trial websites (such as ClinicalTrials.gov), found that 31% of 
trials displayed some evidence of discrepancies between the out-
comes registered and the outcomes published6. Therefore, even trial 
registration may not be a complete barrier to selective outcome 
reporting.
ClinicalTrials.gov tracks all changes made to registered protocols. 
The objectives of this study were: to assess the proportion of reg-
istered trials on ClinicalTrials.gov that had the primary outcome 
changed; to assess when the primary outcome was changed in rela-
tion to the listed study start and end dates and to assess whether 
the primary outcome change had any relation to the study sponsor.
Methods
Data source
ClinicalTrials.gov is a publicly available trial registry and results 
database developed and maintained by the US National Library of 
Medicine on behalf of the US National Institutes of Health.
Study sample
We wrote scripts in R to download all interventional clinical studies 
registered with ClinicalTrials.gov as of 25 October 2012. Data from 
the ‘tabular view’ for all studies (e.g. http://clinicaltrials.gov/ct2/
show/record/NCT00548405?term=alemtuzumab+multiple+scleros
is&rank=2) were downloaded, and the information was automati-
cally extracted from each field and used to populate a spreadsheet 
for analysis. This spreadsheet is available in figshare (doi: 10.6084/
m9.figshare.967827). We downloaded data from all interventional 
studies registered with ClinicalTrials.gov as of 25 October 2012 
preventing any bias in study selection (please contact the corre-
sponding author for details on the scripts).
The following information was collected from each study: study 
registration date (the date the study is registered with ClinicalTri-
als.gov); the study start date (defined as the date that enrollment to 
the protocol begins); the primary completion date (defined as the 
anticipated or actual date the final subject was examined or received 
an intervention for the purposes of final collection of data for the 
primary outcome, whether the clinical trial concluded according 
to the pre-specified protocol or was terminated); study completion 
date (defined as the final date on which data was collected); origi-
nal primary outcome (defined as a specific key measurement(s) or 
observation(s) used to measure the effect of experimental variables 
in a study) and date submitted; current primary outcome and date 
submitted; study phase (phase of investigation as defined by the US 
FDA), data monitoring committee (whether an independent group 
of scientists has been appointed to monitor the safety and the sci-
entific integrity of a human research intervention, and to make rec-
ommendations to the sponsor regarding the termination of the trial 
for efficacy, for harm or for futility); study sponsor (defined as the 
primary organization that oversees the implementation of the study 
and is responsible for data analysis) and collaborators (defined as 
other organizations (if any) providing support, including funding, 
design, implementation, data analysis and reporting).
For studies to be included in this analysis a primary outcome had 
to be registered. A study was classified as not having a primary out-
come changed if the original primary outcome was listed as ‘same 
as current’. For a subset of interventional trials, specifically those 
that had ‘multiple sclerosis’ or ‘diabetes’ in the title, we looked for 
primary outcomes that had a significant change, as the authors have 
experience in these fields. We defined a discrepancy between pri-
mary outcomes if the two were clearly different (e.g. in one study 
the primary outcome was changed from ‘expanded disability status 
scores assessed every 12 weeks’ to ‘annualized relapse rate’). Two 
authors (SVR and JP) independently assessed whether or not the 
studies had significant changes; then they met to compare results. 
For any discrepancies they met with another author (LH) and a con-
sensus was reached. The kappa statistic for agreement between the 
first two observers was 0.87.
ClinicalTrials.gov stores funding organization information using 
two data elements: lead sponsor (defined as the organization or 
person who oversees the clinical study and is responsible for ana-
lyzing the study data) and collaborator (defined as an organization 
other than the sponsor that provides support for a clinical study). 
We derived probable funding source from the lead sponsor and col-
laborator fields using the following algorithm: if the lead sponsor 
and any collaborators were from industry and no non-industry spon-
sors or collaborators were listed, then the study was categorized as 
industry funded; if the lead sponsor and/or collaborator included 
industry and non-industry sources, then the study was categorized 
as mixed; finally if the lead sponsor and any collaborators were 
not from industry and no industry sponsors or collaborators were 
listed, then the study was categorized as non-industry funded. Two 
authors (SVR and JP) independently appraised the funding status 
of all studies; then they met to compare results. For any discrepan-
cies they consulted another author (LH) and a final consensus was 
reached. The kappa statistic for agreement between the first two 
observers was 0.76.
Statistical analysis. We used logistic regression to calculate odds 
ratios (ORs) and 95% confidence intervals (95% CI) for compari-
sons between outcome changed and non-outcome changed groups, 
using registration date and funding source as explanatory variables. 
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had their primary outcome changed after the study had supposedly 
started. Funding source and registration year were associated with 
trials that had their primary outcome changed after the study start 
date (Table 2). Restricting analyses to completed trials (39236 tri-
als) did not affect the associations with funding (mixed funding 
OR=1.01; 95% CI=0.94–1.09, p=0.70; industry funding OR=1.29, 
95% CI=1.23–1.35, p<0.001).
Primary outcome changes in relation to study end date
The dates of primary outcome changes were then compared to the 
listed study end dates. The results showed that 11,834 studies (30.4% 
of 38,974 studies with a registered primary completion date) had 
their primary outcome changed after the primary completion date 
and 10,623 (26.2% of 40,615 studies with a registered study com-
pletion date) studies had their primary outcome changed after the 
study completion date. Funding source and registration year were 
associated with trials that had their primary outcome changed after 
either study completion dates (Table 2). Restricting analyses to 
completed trials (32,124 trials with a primary completion date and 
35,719 trials with a study completion date) rendered the associa-
tions with mixed funding non-significant (primary completed trials 
mixed funding OR=1.10; 95% CI=0.99–1.19, p=0.057; completed 
trials mixed funding OR=1.08, 95% CI=0.99–1.17, p=0.085); the 
associations with industry funding remained (primary completed 
trials industry funding OR=1.94; 95% CI=1.83–2.05, p<0.001; 
completed trials industry funding OR=1.81, 95% CI=1.72–1.91, 
p<0.001).
Inclusion of study phase and use of a data monitoring 
committee
In a full model we included study phase and the use of a data moni-
toring committee (DMC) as additional explanatory variables. There 
were 48,471 trials that provided information for all four variables, 
In a full model, we included study phase and data monitoring com-
mittee as additional explanatory variables. The p-values <0.05 were 
interpreted as significant. Statistical analyses were conducted using 
the STATA 12.0.0 software.
Data set of primary outcome changes in interventional clinical 
trials registered on ClinicalTrials.org
http://dx.doi.org/10.6084/m9.figshare.967827 
Results
Study sample
As of 25 October 2012, 97,668 interventional trials were registered 
with ClinicalTrials.gov. These trials were registered between 1999 
and 2012; the distribution of registrations by year is shown in Table 1. 
There were 46,803 (52.5%) trials classed as non-industry funded, 
11,986 (13.4%) as mixed and 30,415 (34.1%) as industry funded 
(Table 1). There were 39,992 studies registered as completed.
Primary outcome changes
We found that 28,129 studies (31.7% of 89,204) had their primary 
outcome changed. Funding source and registration year were associ-
ated with trials that had their primary outcome changed (Table 2). 
Restricting analyses to completed trials (39,992 trials) did not 
materially change these associations (mixed funding odds ratio 
(OR)=1.02; 95% confidence interval (CI)=0.95–1.10, p=0.63; 
industry funding OR=1.30, 95% CI=1.24–1.36, p<0.001).
Primary outcome changes in relation to study start date
The dates of primary outcome changes were first compared in 
relation to the registered study start date. This analysis showed that 
26,457 studies (30.3% of 87384 studies with a registered start date) 
Table 1. Number of interventional studies registered on ClinicalTrials.gov by year, funding 
status and primary outcome change.
Publicly funded Mixed funding Industry funded
Year Unchanged Changed Unchanged Changed Unchanged Changed
1999 286 142 19 1 3 6
2000 88 91 17 6 1 0
2001 85 141 6 1 3 7
2002 127 186 26 22 137 94
2003 139 333 15 20 125 108
2004 152 460 17 30 250 248
2005 2017 2775 767 860 1817 1717
2006 1519 2402 437 696 1223 1897
2007 2055 2798 563 885 1168 2473
2008 4761 1304 1170 360 2882 1750
2009 5042 1146 1337 314 2742 1254
2010 5609 890 1412 254 2868 850
2011 6184 548 1458 146 3367 463
2012 5241 282 1088 59 2752 210
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outcome changes after listed study start date (OR=4.75, 95% CI 
2.04–11.05, p<0.001), primary outcome changes after listed pri-
mary completion date (OR=14.3, 95% CI 1.87–109.3, p=0.01), 
and primary outcome changes after listed study completion date 
(OR=14.52, 95% CI 1.90–111.06, p=0.01). These associations 
remained also when adjusting for presence of DMC and study 
phase and when looking at completed trials.
Significant primary outcome changes in diabetes 
interventional trials
A subset of interventional trials in diabetes was also investigated 
to assess the actual change in primary outcome. Two hundred and 
forty eight out of 2836 (8.7%) registered trials were deemed to have 
a significant change in the primary outcome, 225 out of 2786 (8.1%) 
were changed after the study start date, 158 out of 1475 (10.7%) 
were changed after the primary completion date and 147 out of 
1561 (9.4%) were changed after the study completion date. After 
adjusting for study registration year, industry funding was associ-
ated to all primary outcome changes (OR=1.76, 95% CI 1.31–2.36, 
p<0.001), primary outcome changes after listed study start date 
(OR=1.75, 95% CI 1.28–2.38, p<0.001), primary outcome changes 
after listed primary completion date (OR=1.83, 95% CI 1.20–2.77 
p=0.005), and primary outcome changes after listed study completion 
47,748 trials that also had a study start date, 23,080 that also had a 
primary completion date and 21,747 that also had a study comple-
tion date. Funding source was associated to all primary outcome 
changes, primary outcome changes after listed study start date and 
primary outcome changes after listed primary completion date fol-
lowing adjustment for study phase and presence of a DMC (Table 3). 
Study phase and use of a DMC were also associated to primary 
outcome changes. All associations remained similar when restrict-
ing to completed trials, although the associations of mixed funding 
with all primary outcome changes and primary outcome changes 
after study start date became non-significant.
Significant primary outcome changes in multiple sclerosis 
interventional trials
A subset of interventional trials in multiple sclerosis was inves-
tigated to assess the actual change in primary outcome. Fifty out 
of 422 (11.9%) registered trials were deemed to have a significant 
change in the primary outcome, 49 out of 416 (11.8%) were changed 
after the study start date, 32 out of 187 (17.1%) were changed 
after the primary completion date and 26 out of 191 (13.6%) were 
changed after the study completion date. After adjusting for study 
registration year, industry funding was associated with all primary 
outcome changes (OR=4.92, 95% CI 2.12–11.41, p<0.001), primary 
Table 2. Association of funding status and registration year with primary outcome change for a) all primary outcome changes, 
b) primary outcome changes after listed study start date, c) primary outcome changes after listed primary completion date on 
ClinicalTrials.gov and d) primary outcome changes after listed study completion date on ClinicalTrials.gov. OR=odds ratio.
a) OR (95% 
confidence 
interval)
p value
b) OR (95% 
confidence 
interval)
p value
c) OR (95% 
confidence 
interval)
p value
d) OR (95% 
confidence 
interval)
p value
Funding 
Non-industry 1 1 1 1
Mixed 1.01 (0.96–1.06) 0.33 1.01 (0.96–1.07) 0.60 1.08 (1.00–1.17) 0.04 1.10 (1.02–1.18) 0.019
Industry 1.36 (1.31–1.41) <0.001 1.37 (1.32–1.42) <0.001 1.84 (1.75–1.94) <0.001 1.82 (1.73–1.91) <0.001
Registration 
Year 
1999 1 1 1 1
2000 1.90 (1.36–2.66) <0.001 1.62 (1.15–2.28) 0.006 1.14 (0.71–1.82) 0.59 1.41 (0.79–2.53) 0.25
2001 3.26 (2.36–4.50) <0.001 3.02 (2.16–4.21) <0.001 1.79 (1.13–2.82) 0.012 1.95 (1.11–3.45) 0.021
2002 1.92 (1.49–2.48) <0.001 1.62 (1.25–2.10) <0.001 1.69 (1.16–2.47) 0.007 1.81 (1.18–2.77) 0.007
2003 3.13 (2.45–4.00) <0.001 2.74 (2.13–3.53) <0.001 2.37 (1.64–3.42) <0.001 2.74 (1.80–4.17) <0.001
2004 3.22 (2.56–4.06) <0.001 2.74 (2.17–3.47) <0.001 2.37 (1.67–3.36) <0.001 2.59 (1.73–3.87) <0.001
2005 2.17 (1.78–2.65) <0.001 1.86 (1.51–2.28) <0.001 2.61 (1.90–3.58) <0.001 2.02 (1.39–2.94) <0.001
2006 2.91 (2.38–3.56) <0.001 2.47 (2.01–3.04) <0.001 2.29 (1.67–3.15) <0.001 2.24 (1.54–3.26) <0.001
2007 3.03 (2.48–3.70) <0.001 2.41 (1.96–2.96) <0.001 1.61 (1.17–2.21) 0.003 2.00 (1.38–2.90) <0.001
2008 0.71 (0.58–0.87) 0.001 0.58 (0.47–0.71) <0.001 0.68 (0.50–0.94) 0.019 1.10 (0.76–1.60) 0.62
2009 0.55 (0.45–0.68) <0.001 0.43 (0.35–0.53) <0.001 0.52 (0.38–0.71) <0.001 0.89 (0.61–1.29) 0.54
2010 0.38 (0.31–0.46) <0.001 0.27 (0.22–0.34) <0.001 0.32 (0.23–0.45) <0.001 0.56 (0.39–0.83) 0.003
2011 0.20 (0.16–0.24) <0.001 0.12 (0.10–0.15) <0.001 0.14 (0.10–0.20) <0.001 0.24 (0.16–0.36) <0.001
2012 0.11 (0.09–0.14) <0.001 0.06 (0.04–0.07) <0.001 0.16 (0.11–0.23) <0.001 0.27 (0.18–0.42) <0.001
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date (OR=2.63, 95% CI 1.68–4.11, p<0.001). These associations 
remained also when adjusting for presence of DMC and study 
phase and when looking at completed trials.
Discussion
Summary
We assessed the proportion of primary outcome changes for inter-
ventional trials registered on ClinicalTrials.gov from 1999 to 2012, 
when these changes occurred and whether these changes related 
to funding source. Industry funding was associated with primary 
outcome changes. These associations remained even after adjusting 
for the phase of the study and the presence of a DMC. The changes 
appeared to peak in the period between 2004 and 2007. This may 
suggest that a lower number of trials were registered before this 
time period and perhaps that there was not enough time to accrue 
for changes to be made in more recently registered trials (or that the 
changes made to the protocol decrease over time). When looking at 
significant primary outcome changes, the proportion of trials with 
their outcome changed was much less than all changes; neverthe-
less, industry funding was still associated with significant primary 
outcome changes.
There are many reasons for departures from the initial study proto-
col. Authors should identify and explain any such changes, however 
Table 3. Association of funding status, registration year, use of a data monitoring committee and study phase with a) all primary 
outcome changes, b) primary outcome changes after listed study start date, c) primary outcome changes after listed primary 
completion date on ClinicalTrials.gov and d) primary outcome changes after listed study completion date on ClinicalTrials.gov. 
OR=odds ratio.
a) OR (95% 
confidence 
interval)
p value
b) OR (95% 
confidence 
interval)
p value
c) OR (95% 
confidence 
interval)
p value
d) OR (95% 
confidence 
interval)
p value
Funding 
Non-industry 1 1 1 1
Mixed 1.07 (1.00–1.15) 0.04 1.08 (1.01–1.16) 0.024 1.01 (0.91–1.12) 0.84 1.08 (0.97–1.19) 0.15
Industry 1.65 (1.56–1.73) <0.001 1.69 (1.60–1.78) <0.001 1.73 (1.61–1.86) <0.001 1.74 (1.62–1.88) <0.001
Registration 
Year 
1999 1 1 1 1
2000 1.38 (0.82–2.34) 0.23 1.35 (0.80–2.29) 0.26 1.15 (0.63–2.08) 0.65 0.95 (0.47–1.92) 0.88
2001 2.73 (1.57–4.72) <0.001 2.67 (1.54–4.64) <0.001 3.00 (1.65–5.44) <0.001 2.19 (1.11–4.31) 0.024
2002 2.69 (1.73–4.19) <0.001 2.61 (1.68–4.07) <0.001 2.55 (1.57–4.13) <0.001 1.82 (1.06–3.14) 0.03
2003 7.01 (4.55–10.8) <0.001 6.76 (4.39–10.43) <0.001 5.92 (3.68–9.50) <0.001 4.27 (2.57–7.12) <0.001
2004 8.80 (5.76–13.45) <0.001 8.56 (5.60–13.09) <0.001 5.99 (3.81–9.41) <0.001 4.88 (2.97–8.02) <0.001
2005 12.33 (8.61–17.66) <0.001 11.64 (8.13–16.69) <0.001 5.82 (3.94–8.59) <0.001 4.69 (3.04–7.24) <0.001
2006 16.34 (11.37–23.47) <0.001 14.91 (10.38–21.43) <0.001 4.22 (2.86–6.23) <0.001 3.84 (2.49–5.93) <0.001
2007 5.26 (3.70–7.47) <0.001 4.73 (3.32–6.73) <0.001 2.21 (1.50–3.25) <0.001 1.82 (1.18–2.81) 0.006
2008 1.11 (0.78–1.58) 0.56 1.01 (0.71–1.43) 0.97 0.93 (0.63–1.36) 0.70 0.94 (0.61–1.45) 0.79
2009 0.85 (0.60–1.21) 0.36 0.74 (0.52–1.05) 0.096 0.70 (0.48–1.04) 0.076 0.78 (0.50–1.20) 0.26
2010 0.58 (0.41–0.83) 0.002 0.47 (0.33–0.67) <0.001 0.43 (0.29–0.64) <0.001 0.49 (0.31–0.76) 0.001
2011 0.30 (0.21–0.43) <0.001 0.21 (0.15–0.30) <0.001 0.16 (0.10–0.24) <0.001 0.17 (0.10–0.27) <0.001
2012 0.16 (0.11–0.23) <0.001 0.09 (0.06–0.13) <0.001 0.22 (0.14–0.36) <0.001 0.24 (0.15–0.41) <0.001
Phase 
0 1 1 1 1
1 1.37 (1.05–1.78) 0.02 1.37 (1.04–1.80) 0.027 1.05 (0.68–1.63) 0.83 1.10 (0.68–1.76) 0.71
2 1.53 (1.18–1.99) 0.001 1.54 (1.17–2.02) 0.002 1.67 (1.08–2.58) 0.02 1.70 (1.06–2.73) 0.028
3 1.63 (1.26–2.13) <0.001 1.62 (1.23–2.13) 0.001 2.22 (1.43–3.44) <0.001 2.22 (1.38–3.57) 0.001
4 1.23 (0.94–1.60) 0.125 1.25 (0.95–1.65) 0.109 2.06 (1.33–3.20) 0.001 2.00 (1.25–3.22) 0.004
DMC 
No 1 1 1 1
Yes 1.17 (1.12–1.23) <0.001 1.13 (1.07–1.19) <0.001 0.82 (0.77–0.88) <0.001 0.81 (0.75–0.86) <0.001
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in the protocol7. The proportion of primary outcome changes that 
we found was perhaps lower than that found previously, but this 
may be due to the different methodology used in this study. The 
relationship between protocol changes and funding has not been 
thoroughly investigated. Chan and colleagues found that 61% of 
the 51 trials with major discrepancies between the study protocol 
and publication were funded solely by industry sources compared 
to 49% of the 51 trials without discrepancies5.
Conclusions
Primary outcome changes are made to study protocols registered 
on ClinicalTrials.gov and these changes are associated with fund-
ing source.
Data availability
figshare: Data set of primary outcome changes in interventional 
clinical trials registered on ClinicalTrials.org8. http://dx.doi.org/10.6084/
m9.figshare.967827
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no such information is given on ClinicalTrials.gov and thus we 
have no explanation for our results. The results obtained here may 
suggest that industry funded trials are more diligent in reporting 
changes to protocols. Indeed, the primary outcome measure data 
element was not available in ClinicalTrials.gov until late 2004 and 
it was considered an optional data element until December 2012. 
There are implications of the data reported here for medical jour-
nals, reviewers and drug approval agencies. 
Limitations of this study
A limitation for our study is the scope of the data. We used data 
from only one trial website, and thus the generalisability to other 
registration sites is unclear. We have also assumed the data entered 
regarding study start and completion dates were accurate. We have 
no information on the reasons for the changes being made. We also 
did not assess the significance of the primary outcome change for 
the vast majority of changes; the sub-studies in multiple sclerosis 
and diabetes suggested that significant changes may only occur in 
approximately 8% of all registered trials, but this may or may not 
be applicable to trials for other disorders. Some primary outcome 
changes may be typographical/semantic and may not reflect actual 
changes to the nature of the outcome (although one would expect 
these to occur equally regardless of funding source).
Background from other studies
Previous reports have not investigated changes to a primary out-
come as entered on a registration website, but they have compared 
trial protocols to published studies. Four previous studies have 
shown that in 47–74% of studies the primary outcome stated in a 
protocol was the same as in a subsequent publication; between 13 
and 31% of primary outcomes specified in the protocol were omit-
ted in the publication and between 10 and 18% of reports intro-
duced a primary outcome in the publication that was not specified 
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This is an interesting report with some interesting results. Upon reading the report it did lead to the
thinking of possible confounding factors which could explain some of the differences if not all. 
Some of the confounding factors could not be easily investigated in the current data set and I will consider
these first.
The first is whether the treatment being investigated in the trial is a licensed or unlicensed
therapy. Though in theory "do-able" the authors can be forgiven for not investigating this. However, could
it be proposed that a trial of a new unlicensed treatment where knowledge is emerging - and being
published as the trial is ongoing - is more likely to have an endpoint changed than a licensed treatment
with known properties?
The other consideration is therapeutic area. The authors to a degree looked into this by investigating two
sub populations of MS and diabetes trials but it could be that certain therapeutic areas predominate in
certain sectors?
One final consideration is if the endpoint change was pre-planned in some way in some form of adaptive
design. 
With respect to confounders which could be investigated the main consideration is study duration. Might a
study that has gone on longer be more likely to have an endpoint change? This could be legitimate if, as
mentioned previously this change is due to published work becoming available. It could also be (maybe)
legitimate if, for completed studies, it has dragged on for an age with no chance to reach the target
sample size. So to a degree there is a case of fitting tailoring the study to what can be answered with the
sample size. The interaction between study duration and funder would also be interesting (as well as just
allowing in the model)
There are two markers in the analysis which do suggest study duration may impact on endpoint
change. The first is study registration year and the other is phase of development. In the case of phase of
development the effect seems to be the reverse, it could be argued, to what one would expect. Early
phase trials are learning trials not confirming trials. A consequence is the endpoints may change to reflect
the properties of a treatment an investigator is learning about in an ongoing manner.  It would be
interesting with study duration in the model how it would effect the comparison of phase of development
Following on from the point in the previous paragraph therefore an analysis of just trials which are Phase
III would be of interest. These trials should have everything set and pre-specified in terms of analysis
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III would be of interest. These trials should have everything set and pre-specified in terms of analysis
One final point about the work is that I could not see mention of a protocol for the audit itself undertaken
for the paper. In particular what the pre-specified primary endpoint and analysis population was. It is not
the convention for audits to do this but it would have been optimal given the subject matter.
In summary therefore it would be optimal to comment on the potential limitations of the work and to
undertake the suggested analyses. However, the work itself is of interest and will almost certainly feed
debate.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 doi:10.5256/f1000research.4053.r4266
This cross-sectional study of trials registered on  found that changes in primary outcomeClinicaltrials.gov
are common and are associated with industry funding. The study was appropriately done and reported.
The reasons for the changes in primary outcomes and the explanation for the association with funding
source are not clear, but it seems likely that changes to the primary outcome might be important for the
sound interpretation of results.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 Janet Wale
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 doi:10.5256/f1000research.4053.r4267
This is a well written, competently undertaken, cross-sectional analysis. The study finds that changes to
primary outcomes listed in a trials register, at any stage of the trial, are clearly associated with industry
funding. Studying the extent of the changes in two disease areas is a practical way used by the authors to
assess the changes and their significance (extensive in some 8%).
The authors point out that there are many reasons for changes from the initial study protocol. No
information is given on ClinicalTrials.gov on the reasons for changes and thus they have no explanation
for their results. The authors suggest that industry funded trials are more diligent in reporting changes to
protocols.
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protocols.
This is a possible area for change which has been provided in this article.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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